NSC 23766 trihydrochloride

目录号：S8031 Purity: 99.96%

NSC 23766 trihydrochloride是一种Rac GTPase抑制剂，通过鸟嘌呤核苷酸因子(GEFs)靶向作用于Rac 活化，无细胞试验中IC50为~50 μM；但是不会抑制密切相关的靶点，Cdc42或RhoA。

NSC 23766 trihydrochloride Chemical Structure

CAS: 1177865-17-6

规格	价格	库存
10mM (1mL in DMSO)	1139.63	现货
10mg	901.16	现货
50mg	3849.78	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.96%

99.96

NSC 23766 trihydrochloride相关产品

相关靶点	Cdc42-subclass Rac Rho-subclass	点击展开
相关产品	CCG-1423 EHop-016 ML141 EHT 1864 2HCl ZCL278 MBQ-167 CCG-203971 Rhosin hydrochloride CID44216842	点击展开
相关化合物库	激酶抑制剂库 PI3K/Akt 抑制剂库 MAPK抑制剂库 DNA损伤/ DNA修复化合物库细胞周期化合物库	点击展开

细胞实验数据示例

细胞系	实验类型	给药浓度	孵育时间	活性描述	文献信息
A431	Growth Inhibition Assay	100 μM	24/48/72 h	inhibits cell growth in a time dependent manner	25109327
RBMECs	Function Assay	100 μM	30 min	blockes 6Bnz-cAMP-mediated activation of Rac1 in EMAP-II-treated RBMECs	26358039
U2-OS	Growth Inhibition Assay	100 μM	24/48/72 h	inhibits cell growth in a time dependent manner	25109327
SW480	Growth Inhibition Assay	100 μM	24/48/72 h	inhibits cell growth in a time dependent manner	25109327
A431	Function Assay	100 μM	24 h	induces cell cycle arrest in the G1 phase	25109327
U2-OS	Function Assay	100 μM	24 h	induces cell cycle arrest in the G1 phase	25109327
SW480	Function Assay	100 μM	24 h	induces cell cycle arrest in the G1 phase	25109327
Ki-67+ CLL	Growth Inhibition Assay	50 µM	5 d	decreases the number of Ki-67+ CLL cells	24501217
NIH3T3	Growth Inhibition Assay	100 μM	24 h	has no significant impact on cell viability	25037060
U87MG	Cell Viability Assay	50 mM	144 h	exhibits synergistic antiproliferative effects combined treatment with erlotinib	23832120
A172MG	Cell Viability Assay	50 mM	144 h	exhibits synergistic antiproliferative effects combined treatment with erlotinib	23832120
T98MG	Cell Viability Assay	50 mM	144 h	exhibits synergistic antiproliferative effects combined treatment with erlotinib	23832120
PC38	Cell Viability Assay	50 mM	144 h	exhibits synergistic antiproliferative effects combined treatment with erlotinib	23832120
U87MG	Function Assay	50 mM	24 h	enhances the antimigratory effect of erlotinib	23832120
PC40	Cell Viability Assay	50 mM	144 h	exhibits synergistic antiproliferative effects combined treatment with erlotinib	23832120
T98MG	Function Assay	50 mM	24 h	enhances the antimigratory effect of erlotinib	23832120
A172MG	Function Assay	50 mM	24 h	enhances the antimigratory effect of erlotinib	23832120
NCI-H1703	Growth Inhibition Assay	0-500 μM	24 h	inhibits cell growth in a dose dependent manner	22549160
NCI-H1703	Function Assay	100 μg/ml	24 h	slows progression through the G1 phase of the cell cycle	22549160
NCI-H1703	Function Assay	0-500 μM	24 h	diminishes basal NF-κB activity dose dependently	22549160
SKBR3	Function Assay	50 μM	24 h	inhibits Rac1 activation	21943825
SKBR3-pMKO.1	Function Assay	50 μM	24 h	inhibits Rac1 activation	21943825
MCF7	Cytotoxicity Assay	0-100 μM	48 h	decreases cell viability in a dose dependent manner	20515940
T47D	Cytotoxicity Assay	0-100 μM	48 h	decreases cell viability in a dose dependent manner	20515940
MDA-MB-468	Cytotoxicity Assay	0-100 μM	48 h	decreases cell viability in a dose dependent manner	20515940
MDA-MB-231	Cytotoxicity Assay	0-100 μM	48 h	decreases cell viability in a dose dependent manner	20515940
MDA-MB-231	Function Assay	0-100 μM	24 h	selectively inhibits Rac1 activation without interfering with the activity of the closely related small GTPase Cdc42	20515940
MDA-MB-231	Function Assay	100 μM	48 h	increases the cell number in G1 phase and decreases the cell number in S and G2-M phases	20515940
MCF7	Function Assay	100 μM	48 h	increases the cell number in G1 phase and decreases the cell number in S and G2-M phases	20515940
MDA-MB-468	Apoptosis Assay	50/100 μM	24 h	induces apoptosis	20515940
T47D	Function Assay	100 μM	48 h	increases the cell number in G1 phase and decreases the cell number in S and G2-M phases	20515940
MDA-MB-468	Function Assay	100 μM	24 h	inhibits caspase-3 activation	20515940
MDA-MB-468	Function Assay	50/100 μM	24 h	increases phosphorylation of JNK in a dose dependent manner	20515940
MDA-MB-231	Function Assay	50/100 μM	24 h	increases phosphorylation of JNK in a dose dependent manner	20515940
MDA-MB-468	Function Assay	50/100 μM	48 h	induces a dose-dependent decrease in phosphorylation of p65 subunit	20515940
MDA-MB-231	Function Assay	50/100 μM	48 h	induces a dose-dependent decrease in phosphorylation of p65 subunit	20515940
IEC-6	Function Assay	120 µM	4/6/8 h	prevents the increased activation of FAK at 6 and 8 h	20448461
RA1	Function Assay	50 μM	24 h	inhibits Matrigel invasion	17622308
RA-FLS (RA2)	Growth Inhibition Assay	25/50 μM	1-9 d	inhibits cell growth in both dose and time dependent manner	17622308
RA2	Function Assay	50 μM	24 h	inhibits Matrigel invasion	17622308
RA4	Function Assay	50 μM	24 h	inhibits Matrigel invasion	17622308
RA3	Function Assay	50 μM	24 h	inhibits Matrigel invasion	17622308
human aortic smooth muscle cells	Function Assay	50 uM		Inhibition of Rac1 binding to Pak1 in human aortic smooth muscle cells at 50 uM by SDS-PAGE based chemiluminescence	19527032
human aortic smooth muscle cells	Function Assay	100 μM		Inhibition of Rac1 binding to Pak1 in human aortic smooth muscle cells at 100 uM by SDS-PAGE based chemiluminescence	19527032
点击查看更多细胞系数据

生物活性

产品描述

靶点

Rac GTPase ^[1]
(Cell-free assay)

50 μM

化学信息&溶解度

分子量	530.97	分子式	C₂₄H₃₅N₇.3ClH
CAS号	1177865-17-6	SDF	Download NSC 23766 trihydrochloride SDF
Smiles	CCN(CC)CCCC(C)NC1=NC(=CC(=N1)NC2=CC3=C(C=C(N=C3C=C2)C)N)C.Cl.Cl.Cl
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 100 mg/mL ( (188.33 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : 100 mg/mL (188.33 mM)

Ethanol : Insoluble

DMSO : 100 mg/mL ( (188.33 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : 100 mg/mL (188.33 mM)

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):